MDGL (Madrigal Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MDGL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Shannon T Kelley | General Counsel | Sell | — | — |
| 2026-08-18 | JOHN C REED | Director | A | — | — |
| 2026-07-20 | William John Sibold | President and CEO | MIXED | — | — |
| 2026-06-18 | JACQUALYN A FOUSE | Director | A | — | — |
| 2026-06-18 | Richard S Levy | Director | A | — | — |
| 2026-06-18 | Daniel J. Brennan | Director | A | — | — |
| 2026-06-18 | Rebecca Taub | Director | A | — | — |
| 2026-06-18 | Baker Brothers Life Sciences LP | Director | A | — | — |
| 2026-06-18 | James M Daly | Director | A | — | — |
| 2026-06-01 | David Soergel | Chief Medical Officer | Sell | — | — |
| 2026-05-22 | Richard S Levy | Director | Sell | — | — |
| 2026-05-18 | David Soergel | Chief Medical Officer | Sell | — | — |
| 2026-03-06 | David Soergel | Chief Medical Officer | A | — | — |
| 2026-03-06 | William John Sibold | President and CEO | MIXED | — | — |
| 2026-03-06 | Rebecca Taub | Director | Sell | — | — |
| 2026-03-06 | Carole Huntsman | Chief Commercial Officer | MIXED | — | — |
| 2026-03-06 | Shannon T Kelley | General Counsel | MIXED | — | — |
| 2026-03-06 | Mardi Dier | EVP and CFO | MIXED | — | — |
| 2026-03-02 | Mardi Dier | EVP and CFO | Sell | — | — |
| 2026-02-24 | Richard S Levy | Director | M | — | — |
| 2026-01-26 | Rebecca Taub | Director | Sell | — | — |
| 2026-01-26 | Carole Huntsman | Chief Commercial Officer | Sell | — | — |
| 2026-01-26 | Richard S Levy | Director | M | — | — |
| 2026-01-26 | William John Sibold | President and CEO | Sell | — | — |
| 2026-01-20 | Shannon T Kelley | General Counsel | Sell | — | — |
| 2026-01-20 | Rita Thakkar | Chief Accounting Officer | A | — | — |
| 2026-01-20 | Rebecca Taub | Director | Sell | — | — |
| 2026-01-13 | Rebecca Taub | Director | MIXED | — | — |
| 2026-01-13 | PAUL A FRIEDMAN | Director | MIXED | — | — |
| 2026-01-13 | PAUL A FRIEDMAN | Director | MIXED | — | — |
| 2026-01-13 | Rebecca Taub | Director | MIXED | — | — |
| 2025-12-12 | Rebecca Taub | Director | MIXED | — | — |
| 2025-12-12 | PAUL A FRIEDMAN | Director | MIXED | — | — |
| 2025-12-04 | William John Sibold | President and CEO | MIXED | — | — |
| 2025-12-03 | Mardi Dier | EVP and CFO | MIXED | — | — |
| 2025-11-21 | Carole Huntsman | Chief Commercial Officer | Sell | — | — |
| 2025-11-14 | Richard S Levy | Director | MIXED | — | — |
| 2025-11-07 | KENNETH BATE | Director | MIXED | — | — |
| 2025-09-09 | William John Sibold | President and CEO | Sell | — | — |
| 2025-08-21 | William John Sibold | President and CEO | Sell | — | — |
| 2025-08-20 | 667, L.P. | Director | Buy | — | — |
| 2025-08-20 | Baker Brothers Life Sciences LP | Director | Buy | — | — |
| 2025-08-18 | Shannon T Kelley | General Counsel | Sell | — | — |
| 2025-08-15 | KENNETH BATE | Director | MIXED | — | — |
| 2025-08-13 | PAUL A FRIEDMAN | Director | MIXED | — | — |
| 2025-08-13 | PAUL A FRIEDMAN | Director | MIXED | — | — |
| 2025-08-13 | Rebecca Taub | Director | MIXED | — | — |
| 2025-08-05 | Daniel J. Brennan | Director | A | — | — |
| 2025-07-22 | Rebecca Taub | Director | MIXED | — | — |
| 2025-07-22 | PAUL A FRIEDMAN | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,354,058 | — |
| — | Director | 1,948,876 | — |
| — | Director | 1,832,216 | — |
| — | Director | 1,796,261 | — |
| — | Director | 1,668,553 | — |
| — | 10%+ Owner | 1,511,782 | — |
| — | Director | 1,108,207 | — |
| — | Director | 865,744 | — |
| — | Director | 352,779 | — |
| — | President and CEO | 209,610 | — |
| — | Director | 179,279 | — |
| — | Director | 154,255 | — |
| — | Chief Financial Officer | 49,033 | — |
| — | Director | 22,469 | — |
| — | Chief Financial Officer | 18,737 | — |
| — | SVP and General Counsel | 18,221 | — |
| — | Chief Commercial Officer | 15,001 | — |
| — | Senior VP, Chief Pharma Dev. | 14,018 | — |
| — | Chief Commercial Officer | 13,111 | — |
| — | EVP and CFO | 13,086 | — |
| — | General Counsel | 11,474 | — |
| — | Chief Medical Officer | 10,033 | — |
| — | Director | 3,081 | — |
| — | Director | 2,657 | — |
| — | Chief Accounting Officer | 2,398 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MDGL quote page; the site-wide leaderboard is on the insider transactions hub.